Aquestive Therapeutics AQST
$3.46 −$0.25 (-6.61%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.52 +1.73%
Open$3.62
Prev close$3.71
Day range$3.41 – $3.65
Volume3.36M
Market cap$434.88M
P/E (TTM)–
Dividend yield–
Earnings
Average move on report day±7.7%last 16 reports
Closed higher6 of 1638% of the time
Best reaction+20.9%
Worst reaction-19.6%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 3 Nov 2026 | After Market | ±14.8% | -2.06% | Within range |
| 2026/Q2 | 11 Aug 2026 | After Market | ±14.7% | -4.08% | Within range |
| 2026/Q1 | 13 May 2026 | After Market | ±9.1% | +14.53% | Bigger than priced |
| 2025/Q4 | 4 Mar 2026 | After Market | ±16.6% | -2.52% | Within range |
| 2025/Q3 | 5 Nov 2025 | After Market | ±15.7% | +2.17% | Within range |
| 2025/Q2 | 11 Aug 2025 | After Market | ±34.6% | -2.07% | Within range |
| 2025/Q1 | 12 May 2025 | After Market | ±18.6% | -19.65% | Bigger than priced |
| 2024/Q4 | 5 Mar 2025 | After Market | ±24.4% | -7.53% | Within range |
| 2024/Q3 | 4 Nov 2024 | After Market | ±23.3% | -7.67% | Within range |
| 2024/Q2 | 6 Aug 2024 | After Market | ±17.3% | +0.88% | Within range |
| 2024/Q1 | 7 May 2024 | After Market | ±20.3% | -8.73% | Within range |
| 2023/Q4 | 5 Mar 2024 | None | ±50.0% | +20.05% | Within range |
| 2023/Q3 | 6 Nov 2023 | After Market | ±73.0% | +4.91% | Within range |
| 2023/Q2 | 8 Aug 2023 | Pre Market | ±24.4% | -5.37% | Within range |
| 2023/Q1 | 2 May 2023 | After Market | ±121.6% | +20.86% | Within range |
| 2022/Q4 | 7 Mar 2023 | After Market | ±200.0% | +0.00% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$7.56M-41.0% YoY
Operating profit-$14.47M-26.0% YoY
Net profit-$16.50M-6.8% YoY
Diluted EPS-$0.13+7.1% YoY
Free cash flow-$7.63M+40.8% YoY
Operating cash flow-$7.05M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin65.3%
Operating margin-114.1%
Net margin-162.3%
Return on assets-56.0%
Current ratio6.12
Liabilities / assets159.4%
Cash & investments$90.35M
Total debt$58.15M
Net cash (debt)$32.20M
No comments yet — be the first to weigh in on AQST.
Sign in to join the discussion.